Is GlyNAC a better option than NAD+ precursors?

"Better" depends on what you're trying to address, because these two target different cellular problems. NAD+ precursors address energy metabolism and cellular repair capacity. GlyNAC — glycine plus N-acetylcysteine — addresses glutathione deficiency and oxidative stress. They're complementary mechanisms, not competing ones.

That said, GlyNAC has an unusually strong trial record for a supplement, and it's fair to say its human evidence is in some respects more developed than NMN's.

What the GlyNAC trials show. A pilot trial at Baylor College of Medicine supplemented older adults for 24 weeks and reported correction of red blood cell glutathione deficiency, oxidative stress, and mitochondrial dysfunction, alongside improvements in inflammation, endothelial function, insulin resistance, genomic damage, cognition, strength, gait speed, and exercise capacity. A follow-up randomized controlled trial studied 24 older adults and 12 young adults, with older participants randomized to 16 weeks of GlyNAC or an isonitrogenous alanine placebo, and reported improvements across glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, and multiple aging hallmarks. Another RCT found GlyNAC protected older adults against the oxidative stress and inflammation triggered by a single carbohydrate meal.

The important caveat. A separate, larger randomized controlled trial in 117 healthy older adults (aged 60–85) testing three GlyNAC doses over 14 days found a more modest result: GlyNAC was safe and well tolerated, but the meaningful glutathione increases showed up in a post-hoc subgroup — specifically people who started with high oxidative stress and low baseline glutathione. The authors' conclusion was that GlyNAC may increase glutathione levels in older adults with high glutathione demand. That's a real finding, but it's a narrower claim than the headline versions of GlyNAC research suggest, and it mirrors the NAD+ story: the people most likely to benefit are those who are actually deficient.

How to think about choosing. The Baylor trials are small (12–24 participants per arm) and largely from a single research group, which is a genuine limitation — independent replication at scale is still needed. But within those limits, GlyNAC's outcome measures (strength, gait speed, cognition, inflammation markers) are more functionally meaningful than "blood NAD+ went up," which is where most NMN evidence currently sits.

If your concern is oxidative stress, glutathione status, and inflammation, GlyNAC has the more direct evidence. If your interest is cellular energy metabolism and NAD+ decline specifically, precursors address that pathway and GlyNAC doesn't. Neither is a replacement for the other, and there's no strong human data on combining them.

Sources for this question:

• Journals of Gerontology Series A, "Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial" — https://academic.oup.com/biomedgerontology/article/78/1/75/6668639
• Clinical and Translational Medicine, "GlyNAC supplementation in older adults improves glutathione deficiency... Results of a pilot clinical trial" — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002905/
• PubMed record for the pilot trial — https://pubmed.ncbi.nlm.nih.gov/33783984/
• Frontiers, "A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage" (NCT05041179) — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261343/
• Innovation in Aging, "GlyNAC Supplementation in Older Adults Protects From Meal Driven Oxidative Stress and Inflammation: Results of a RCT" — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767229/